Hodgkin's lymphoma epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Removing from Primary care)
 
(19 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Hodgkin's lymphoma}}
{{Hodgkin's lymphoma}}
{{CMG}}; {{AE}} {{Rim}}
{{CMG}}; {{AE}} {{Rim}}, {{AS}}


==Overview==
==Overview==
Unlike some [[non-Hodgkin lymphoma|other lymphomas]], whose [[incidence (epidemiology)|incidence]] increases with age, Hodgkin's lymphoma has a bimodal incidence curve; that is, it occurs most frequently in two separate age groups, the first being young adulthood (age 15&ndash;35) and the second being in those over 55 years old although these peaks may vary slightly with nationality.<ref> {{cite book | last=Mauch | first=Peter | coauthors=James Armitage, Volker Diehl, Richard Hoppe, Laurence Weiss | title=Hodgkin's Disease | publisher=[[Lippincott Williams & Wilkins]] | date=1999 | pages=62-64 | isbn=0-7817-1502-4}} </ref> In 2011, the age-adjusted incidence of Hodgkin's lymphoma was 2.71 per 100,000 persons in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> The incidence of Hodgkin's lymphoma is higher among patients with HIV/AIDS; however, in contrast to many other lymphomas associated with HIV infection, Hodgkin's lymphoma occurs most commonly in patients with higher CD4 T cell counts.<ref>{{cite journal |author=Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA |title=Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS |journal=Blood |volume=108 |issue=12 |pages=3786-91 |year=2006 |pmid=16917006 |doi=10.1182/blood-2006-05-024109}}</ref>
Hodgkin's lymphoma has a bimodal age distribution that differs geographically and ethnically in industrialized countries; the early peak occurs in the middle-to-late 20s and the second peak after age 50 years. In developing countries, the early peak occurs before adolescence.<ref name=NCI>{{cite web | title = National Caner Institute Childhood Hodgkin Lymphoma Treatment| url =http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq#cit/section_1.3}}</ref> In 2015, the incidence of Hodgkins lymphoma was estimated to be 3 cases per 100,000 individuals in the United States.<ref name=NCI>{{cite web | title = National Caner Institute Adult Hodgkin Lymphoma Treatment| url =http://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq}}</ref> The incidence of Hodgkin's lymphoma is higher among patients with [[HIV]]/[[AIDS]]; however, in contrast to many other lymphomas associated with [[HIV infection]], Hodgkin's lymphoma occurs most commonly in patients who do not have severe immunosupression.<ref>{{cite journal |author=Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA |title=Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS |journal=Blood |volume=108 |issue=12 |pages=3786-91 |year=2006 |pmid=16917006 |doi=10.1182/blood-2006-05-024109}}</ref>  
 
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Prevalence===
===Prevalence===
 
* In the United States, the age-adjusted prevalence of Hodgkin's lymphoma is 35 per 100,000 in 2011.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
* In the United States, the age adjusted prevalence of Hodgkin's lymphoma is 0.035% in 2011.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>


===Incidence===
===Incidence===
 
* In 2015, the incidence of Hodgkins lymphoma was estimated to be 3 cases per 100,000 individuals in the United States.<ref name=NCI>{{cite web | title = National Caner Institute Adult Hodgkin Lymphoma Treatment| url =http://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq}}</ref>
* The delay-adjusted incidence of Hodgkin's lymphoma in 2011 was estimated to be 2.8 per 100,000 persons in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
 
* In 2011, the age-adjusted incidence of Hodgkin's lymphoma was 2.71 per 100,000 persons in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>


===Age===
===Age===
 
* Hodgkin's lymphoma has a bimodal age distribution that differs geographically and ethnically in industrialized countries; the early peak occurs in the middle-to-late 20s and the second peak after age 50 years. In developing countries, the early peak occurs before adolescence.<ref name=NCI>{{cite web | title = National Caner Institute Childhood Hodgkin Lymphoma Treatment| url =http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq#cit/section_1.3}}</ref>
* While the overall age adjusted incidence of Hodgkin's lymphoma in the United States between 2007 and 2011 is 2.7 per 100,000, the age-adjusted incidence of Hodgkin's lymphoma by age category is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
* The incidence of Hodgkin's lymphoma is estimated to be 2.9 cases per 100,000 adolescents among ages 15 to 19 years in the United States.
* The incidence of Hodgkin's lymphoma is estimated to be 0.9 cases per 100,000 children among ages 10 to 14 years in the United States.
* The incidence of Hodgkin's lymphoma is estimated to be 0.3 cases per 100,000 children among ages 5 to 9 years in the United States.
* The incidence of Hodgkin's lymphoma is estimated to be 0.09 cases per 100,000 children among 4 years of age in the United States.
* While the overall age-adjusted incidence of Hodgkin's lymphoma in the United States between 2007 and 2011 is 2.7 per 100,000, the age-adjusted incidence of Hodgkin's lymphoma by age category is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
** Between 20 and 29 years: 4.1-4,5 per 100,000
** Between 20 and 29 years: 4.1-4,5 per 100,000
** Under 65 years: 2.5 per 100,000
** Under 65 years: 2.5 per 100,000
Line 25: Line 24:


===Gender===
===Gender===
 
* In children <5 year, males are more commonly affected with Hodgkin's lymphoma than females. The male to female ratio is approximately 5.3.<ref name=NCI>{{cite web | title = National Caner Institute Childhood Hodgkin Lymphoma Treatment| url =http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq#cit/section_1.3}}</ref>
* In the United States, the age adjusted prevalence of Hodgkin's lymphoma by gender in 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
* In children aged 15 to 19 year, females are more commonly affected with Hodgkin's lymphoma than males. The male to female ratio is approximately 0.8.
** In males: 0.0372%
* In the United States, the age-adjusted prevalence of Hodgkin's lymphoma by gender in 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
** In females: 0.0331%
** In males: 37.2 per 100,000
 
** In females: 33.1 per 100,000
* In the United States, the age-adjusted incidence of Hodgkin's lymphoma by gender on 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
** In males: 3.11 per 100,000 persons
** In females: 2.34 per 100,000 persons
* In the United States, the delay-adjusted incidence of Hodgkin's lymphoma by gender in 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
* In the United States, the delay-adjusted incidence of Hodgkin's lymphoma by gender in 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
** In males: 3.22 per 100,000 persons
** In males: 3.22 per 100,000 persons
** In females: 2.42 per 100,000 persons
** In females: 2.42 per 100,000 persons
* In the United States, the age-adjusted incidence of Hodgkin's lymphoma by gender on 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
** In males: 3.11 per 100,000 persons
** In females: 2.34 per 100,000 persons
Shown below is an image depicting the delay-adjusted incidence and observed incidence of Hodgkin's lymphoma by gender and race in the United States between 1975 and 2011.  These graphs are adapted from [[SEER]]: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
Shown below is an image depicting the delay-adjusted incidence and observed incidence of Hodgkin's lymphoma by gender and race in the United States between 1975 and 2011.  These graphs are adapted from [[SEER]]: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>


Line 43: Line 40:


===Race===
===Race===
 
* Shown below is a table depicting the age-adjusted prevalence of Hodgkin's lymphoma by race in 2011 in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
* Shown below is a table depicting the age adjusted prevalence of Hodgkin's lymphoma by race in 2011 in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>


{| style="cellpadding=0; cellspacing= 0; width: 600px;"
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
Line 50: Line 46:
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center | || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''All Races''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''White''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Black''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Asian/Pacific Islander'''  || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Hispanic'''  
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center | || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''All Races''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''White''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Black''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Asian/Pacific Islander'''  || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Hispanic'''  
|-
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Age-adjusted prevalence'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.035% ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.04% ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.0321%||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.0126% ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.0236%
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Age-adjusted prevalence'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |35 per 100,000 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |40 per 100,000 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |32.1 per 100,000||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |12.6 per 100,000 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |23.6 per 100,000
|}
|}


Line 61: Line 57:
==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


[[Category:Disease]]
[[Category:Disease]]
Line 66: Line 65:
[[Category:Types of cancer]]
[[Category:Types of cancer]]
[[Category:Rare diseases]]
[[Category:Rare diseases]]
[[Category:Mature chapter]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Mature chapter]]
[[Category:Medicine]]
[[Category:primary care]]
[[Category:Immunology]]
[[Category:Needs overview]]
 
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 22:13, 29 July 2020

Hodgkin's lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hodgkin's lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray Findings

CT

MRI

Ultrasound

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hodgkin's lymphoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hodgkin's lymphoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hodgkin's lymphoma epidemiology and demographics

CDC on Hodgkin's lymphoma epidemiology and demographics

Hodgkin's lymphoma epidemiology and demographics in the news

Blogs on Hodgkin's lymphoma epidemiology and demographics

Directions to Hospitals Treating Hodgkin's lymphoma

Risk calculators and risk factors for Hodgkin's lymphoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2], Sowminya Arikapudi, M.B,B.S. [3]

Overview

Hodgkin's lymphoma has a bimodal age distribution that differs geographically and ethnically in industrialized countries; the early peak occurs in the middle-to-late 20s and the second peak after age 50 years. In developing countries, the early peak occurs before adolescence.[1] In 2015, the incidence of Hodgkins lymphoma was estimated to be 3 cases per 100,000 individuals in the United States.[1] The incidence of Hodgkin's lymphoma is higher among patients with HIV/AIDS; however, in contrast to many other lymphomas associated with HIV infection, Hodgkin's lymphoma occurs most commonly in patients who do not have severe immunosupression.[2]

Epidemiology and Demographics

Prevalence

  • In the United States, the age-adjusted prevalence of Hodgkin's lymphoma is 35 per 100,000 in 2011.[3]

Incidence

  • In 2015, the incidence of Hodgkins lymphoma was estimated to be 3 cases per 100,000 individuals in the United States.[1]

Age

  • Hodgkin's lymphoma has a bimodal age distribution that differs geographically and ethnically in industrialized countries; the early peak occurs in the middle-to-late 20s and the second peak after age 50 years. In developing countries, the early peak occurs before adolescence.[1]
  • The incidence of Hodgkin's lymphoma is estimated to be 2.9 cases per 100,000 adolescents among ages 15 to 19 years in the United States.
  • The incidence of Hodgkin's lymphoma is estimated to be 0.9 cases per 100,000 children among ages 10 to 14 years in the United States.
  • The incidence of Hodgkin's lymphoma is estimated to be 0.3 cases per 100,000 children among ages 5 to 9 years in the United States.
  • The incidence of Hodgkin's lymphoma is estimated to be 0.09 cases per 100,000 children among 4 years of age in the United States.
  • While the overall age-adjusted incidence of Hodgkin's lymphoma in the United States between 2007 and 2011 is 2.7 per 100,000, the age-adjusted incidence of Hodgkin's lymphoma by age category is:[3]
    • Between 20 and 29 years: 4.1-4,5 per 100,000
    • Under 65 years: 2.5 per 100,000
    • 65 and over: 4.2 per 100,000

Gender

  • In children <5 year, males are more commonly affected with Hodgkin's lymphoma than females. The male to female ratio is approximately 5.3.[1]
  • In children aged 15 to 19 year, females are more commonly affected with Hodgkin's lymphoma than males. The male to female ratio is approximately 0.8.
  • In the United States, the age-adjusted prevalence of Hodgkin's lymphoma by gender in 2011 is:[3]
    • In males: 37.2 per 100,000
    • In females: 33.1 per 100,000
  • In the United States, the age-adjusted incidence of Hodgkin's lymphoma by gender on 2011 is:[3]
    • In males: 3.11 per 100,000 persons
    • In females: 2.34 per 100,000 persons
  • In the United States, the delay-adjusted incidence of Hodgkin's lymphoma by gender in 2011 is:[3]
    • In males: 3.22 per 100,000 persons
    • In females: 2.42 per 100,000 persons

Shown below is an image depicting the delay-adjusted incidence and observed incidence of Hodgkin's lymphoma by gender and race in the United States between 1975 and 2011. These graphs are adapted from SEER: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.[3]

The delay-adjusted incidence and observed incidence of Hodgkin's lymphoma by gender and race in the United States

Race

  • Shown below is a table depicting the age-adjusted prevalence of Hodgkin's lymphoma by race in 2011 in the United States.[3]
All Races White Black Asian/Pacific Islander Hispanic
Age-adjusted prevalence 35 per 100,000 40 per 100,000 32.1 per 100,000 12.6 per 100,000 23.6 per 100,000

Shown below is an image depicting the incidence of Hodgkin's lymphoma by race in the United States between 1975 and 2011.[3]

The incidence of Hodgkin's lymphoma by race in the United States between 1975 and 2011

API: Asian/Pacific Islander; AI/AN: American Indian/ Alaska Native

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "National Caner Institute Childhood Hodgkin Lymphoma Treatment".
  2. ↑ Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA (2006). "Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS". Blood. 108 (12): 3786–91. doi:10.1182/blood-2006-05-024109. PMID 16917006.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Hodgkin%27s_lymphoma_epidemiology_and_demographics&oldid=1639438"